WHO Classification of Tumours Editorial Board. Breast tumours[M]. 5th ed. Lyon: International Agency for Research on Cancer, 2019.

GRADISHAR W J, MORAN M S, ABRAHAM J, et al. Breast Cancer, Version 3.2024, NCCN clinical practice guidelines in oncology[J]. J Natl Compr CancNetw, 2024, 22(5): 331-357.

American Joint Committee on Cancer. AJCC cancer staging handbook[M]. 7th ed. Chicago: Springer, 2010.

BUCHHOLZ T A, SOMERFIELD M R, GRIGGS J J, et al. Margins for breast-conserving surgery with whole-breast irradiation in stage Ⅰ and Ⅱ invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline[J]. J Clin Oncol, 2014, 32(14): 1502-1506.

KUNKLER I H, WILLIAMS L J, JACK W J, et al. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME Ⅱ): a randomised controlled trial[J]. Lancet Oncol, 2015, 16(3): 266-273.

GIULIANO A E, MCCALL L, BEITSCH P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial[J]. Ann Surg, 2010, 252(3): 426-432; discussion 432-433.

DONKER M, VAN TIENHOVEN G, STRAVER M E, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial[J]. Lancet Oncol, 2014, 15(12): 1303-1310.

MORAN M S, SCHNITT S J, GIULIANO A E, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages Ⅰ and Ⅱ invasive breast cancer[J]. J Clin Oncol, 2014, 32(14): 1507-1515.

EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP EBCTCG. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials[J]. Lancet Oncol, 2018, 19(1): 27-39.

GIANNI L, PIENKOWSKI T, IM Y H, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (Neo Sphere): a multicentre, open-label, phase 2 randomised trial[J]. Lancet Oncol, 2016, 17(6): 791-800.

SIKOV W M, BERRY D A, PEROU C M, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage Ⅱ to Ⅲ triple-negative breast cancer: CALGB 40603 (Alliance)[J]. J Clin Oncol, 2015, 33(1): 13-21.

ADAMS S, LOI S, TOPPMEYER D, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phaseⅡ KEYNOTE-086 study[J]. Ann Oncol, 2019, 30(3): 405-411.

ADAMS S, SCHMID P, RUGO H S, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase Ⅱ KEYNOTE-086 study[J]. Ann Oncol, 2019, 30(3): 397-404.

GOETZ M P, TOI M, CAMPONE M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer[J]. J Clin Oncol, 2017, 35(32): 3638-3646.

ROBSON M, IM S A, SENKUS E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation[J ] . N Engl J Med, 2017, 377(6): 523-533.

SLEDGE G W Jr, TOI M, NEVEN P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR + /HER2 - advanced breast cancer who had progressed while receiving endocrine therapy[J ] . J Clin Oncol, 2017, 35(25): 2875-2884.

SCHMID P, ADAMS S, RUGO H S, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer[J]. N Engl J Med, 2018, 379(22): 2108-2121.

TRIPATHY D, IM S A, COLLEONI M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial[J]. Lancet Oncol, 2018, 19(7): 904-915.

TURNER N C, SLAMON D J, RO J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer[J]. N Engl J Med, 2018, 379(20): 1926-1936.

BLOK E J, KROEP J R, MEERSHOEK-KLEIN KRANENBARG E, et al. Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL trial (BOOG 2006-05)[J]. J Natl Cancer Inst, 2018, 110(1).

BURSTEIN H J, LACCHETTI C, ANDERSON H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update[J]. J Clin Oncol, 2019, 37(5): 423-438.

FRANCIS P A, PAGANI O, FLEMING G F, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer[J]. N Engl J Med, 2018, 379(2): 122-137.

GNANT M, MLINERITSCH B, STOEGER H, et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group trial 12[J]. Ann Oncol, 2015, 26(2): 313-320.

MAMOUNAS E P, BANDOS H, LEMBERSKY B C, et al. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20(1): 88-99.

METZGER FILHO O, GIOBBIE-HURDER A, MALLON E, et al. Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial[J]. J Clin Oncol, 2015, 33(25): 2772-2779.

PAN H C, GRAY R, BRAYBROOKE J, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years[J]. N Engl J Med, 2017, 377(19): 1836-1846.

BLUM J L, FLYNN P J, YOTHERS G, et al. Anthracyclines in early breast cancer: the ABC trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG oncology)[J]. J Clin Oncol, 2017, 35(23): 2647-2655.

CARDOSO F, VAN'T VEER L J, BOGAERTS J, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer[J]. N Engl J Med, 2016, 375(8): 717-729.

EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP EBCTCG.Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials[J]. Lancet, 2015, 386(10001): 1353-1361.

EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP EBCTCG.Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37298 women with early breast cancer in 26 randomised trials[J]. Lancet, 2019, 393(10179): 1440-1452.

LOIBL S, WEBER K E, TIMMS K M, et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from Gepar Sixto[J]. Ann Oncol, 2018, 29(12): 2341-2347.

MASUDA N, LEE S J, OHTANI S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy[J]. N Engl J Med, 2017, 376(22): 2147-2159.

MOORE H C, UNGER J M, PHILLIPS K A, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy[J]. N Engl J Med, 2015, 372(10): 923-932.

NITZ U, GLUZ O, CLEMENS M, et al. West German study Plan B trial: adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early breast cancer[J]. J Clin Oncol, 2019, 37(10): 799-808.

SPARANO J A, GRAY R J, MAKOWER D F, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer[J]. N Engl J Med, 2018, 379(2): 111-121.

PROWELL T M, BEAVER J A, PAZDUR R.Residual disease after neoadjuvant therapy - developing drugs for high-risk early breast cancer[J]. N Engl J Med, 2019, 380(7): 612-615.

SPARANO J A, GRAY R J, RAVDIN P M, et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer[J]. N Engl J Med, 2019, 380(25): 2395-2405.

EARL H M, HILLER L, VALLIER A L, et al. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial[J]. Lancet, 2019, 393(10191): 2599-2612.

MARTIN M, HOLMES F A, EJLERTSEN B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (Exte NET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(12): 1688-1700.

VON MINCKWITZ G, HUANG C S, MANO M S, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer[J]. N Engl J Med, 2019, 380(7): 617-628.

VON MINCKWITZ G, PROCTER M, DE AZAMBUJA E, et al.Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer[J]. N Engl J Med, 2017, 377(2): 122-131.

GIANNI L, PIENKOWSKI T, IM Y H, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (Neo Sphere): a randomised multicentre, open-label, phase 2 trial[J]. Lancet Oncol, 2012, 13(1): 25-32.

MA F, LI Q, CHEN S S, et al. Phase Ⅰ study and biomarker analysis of pyrotinib, a novel irreversible pan-Erb B receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer[J]. J Clin Oncol, 2017, 35(27): 3105-3112.

LANG G T, JIANG Y Z, SHI J X, et al. Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing[J]. Nat Commun, 2020, 11(1): 5679.

JIANG Y Z, MA D, SUO C, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies[J]. Cancer Cell, 2019, 35(3): 428-440.e5.

LI J J, YU K D, PANG D, et al. Adjuvant capecitabine with docetaxel and cyclophosphamide plus epirubicin for triple-negative breast cancer (CBCSG010): an open-label, randomized, multicenter, phase Ⅲ trial[J]. J Clin Oncol, 2020, 38(16): 1774-1784.

YU K D, YE F G, HE M, et al. Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: a phase 3 randomized clinical trial[J]. JAMA Oncol, 2020, 6(9): 1390-1396.

WANG X, WANG S S, HUANG H, et al. Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial[J ] . JAMA, 2021, 325(1): 50-58.

HU X C, ZHANG J, XU B H, et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial[J]. Lancet Oncol, 2015, 16(4): 436-446.

ZHANG J, LIN Y, SUN X J, et al. Biomarker assessment of the CBCSG006 trial: a randomized phase Ⅲ trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer[J]. Ann Oncol, 2018, 29(8): 1741-1747.

LIN M X, CHEN Y, JIN Y Z, et al. Comparative overall survival of CDK4/6 inhibitors plus endocrine therapy vs endocrine therapy alone for hormone receptor-positive, HER2-negative metastatic breast cancer[J ] . J Cancer, 2020, 11(24): 7127-7136.

FALLON M, GIUSTI R, AIELLI F, et al. Management of cancer pain in adult patients: ESMO clinical practice guidelines[J]. Ann Oncol, 2018, 29(Suppl 4): iv166-iv191.

ZHAO S, MA D, XIAO Y, et al. Molecular subtyping of triple-negative breast cancers by immunohistochemistry: molecular basis and clinical relevance[J]. Oncologist, 2020, 25(10): e1481-e1491.

JIANG Y Z, LIU Y, XIAO Y, et al. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial[J]. Cell Res, 2021, 31(2): 178-186.

ALBABTAIN H, ALWHAIBI M, ALBURAIKAN K, et al. Quality of life and complementary and alternative medicine use among women with breast cancer[J]. Saudi Pharm J, 2018, 26(3): 416-421.

林洪生,刘杰,张英.《恶性肿瘤中医诊疗指南》的内涵及其意义[J].中国肿瘤临床与康复,2016,23(3): 257-260.

LIN H S,LIU J,ZHANG Y.Connotation and significance of“Guidelines for Diagnosis and Treatment of Malignant Tumors in Traditional Chinese Medicine”[J]. Chin J Clin Oncol Rehabil,2016,23(3): 257-260.

陈前军,裴晓华.早期乳腺癌中医辨证内治专家共识[J].现代中医临床,2020,27(3): 5-8.

CHEN Q J,PEI X H.Consensus on TCM syndrome differentiation and internal therapy for early-stage breast cancer[J]. Mod Chin Clin Med,2020,27(3): 5-8.

杨雯靖,念家云,杨国旺.中西医结合治疗乳腺癌现状及展望[J].北京中医药,2020,39(10): 1009-1013.

YANG W J,NIAN J Y,YANG G W. Present situation and prospect of treating breast cancer with integrated traditional Chinese and western medicine[J]. Beijing J Tradit Chin Med,2020,39(10): 1009-1013.

马瑞,张丹,林从尧.小金丸、逍遥丸及乳癖散结胶囊治疗乳腺增生的临床观察[J].现代中西医结合杂志,2015,24(2): 140-142.

MA R,ZHANG D,LIN C Y. Clinical observation of Koganemaru,Xiaoyao Pill and Rubisanjie Capsule in the treatment of mammary hyperplasia[J]. Mod J Integr Tradit Chin West Med,2015,24(2): 140-142.

《乳腺癌HER检测指南版》编写组.《乳腺癌HER2检测指南(2019版)》[J].中华病理学杂志,2019,48(3): 169-175.

HER2 Detection Guidline for Breast Cancer (2019 Edition) Writing Group. HER2 guideline for breast cancer (2019 edition)[J]. Chin J Pathol,2019,48(3): 169-175.

《乳腺癌新辅助治疗的病理诊断专家共识2020版》编写组.乳腺癌新辅助治疗的病理诊断专家共识(2020版)[J].中华病理学杂志,2020,49(4): 296-304.

Expert Consensus on Pathological Diagnosis of Neoadjuvant Therapy for Breast Cancer (2020 Edition)Writing Group. Writing Group. Expert consensus on pathological diagnosis of neoadjuvant therapy for breast cancer (2020 edition)[J]. Chin J Pathol,2020,49(4): 296-304.

《乳腺癌雌、孕激素受体检测指南》编写组.乳腺癌雌、孕激素受体检测指南[J].中华病理学杂志,2015,44(4): 237-240.

Guidelines for Detection of Estrogen and Progesterone Receptors in Breast Cancer Writing Group.Guidelines for detection of estrogen and progesterone receptors in breast cancer[J]. Chin J Pathol,2015,44(4): 237-240.

GOLDHIRSCH A, INGLE J N, GELBER R D, et al. Thresholds for therapies: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2009[J]. Ann Oncol, 2009, 20(8): 1319-1329.

GOLDHIRSCH A, WOOD W C, COATES A S, et al. Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011[J]. Ann Oncol, 2011, 22(8): 1736-1747.

GOLDHIRSCH A, WINER E P, COATES A S, et al. Personalizing the treatment of women with early breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2013[J]. Ann Oncol, 2013, 24(9): 2206-2223.

WRIGHT M J, PARK J, FEY J V, et al. Perpendicular inked versus tangential shaved margins in breast-conserving surgery:does the method matter?[J]. J Am Coll Surg, 2007, 204(4): 541-549.

ELSTON C W, ELLIS I O. Pathological prognostic factors in breast cancer.Ⅰ. The value of histological grade in breast cancer: experience from a large study with long-term follow-up[J]. Histopathology, 2002, 41(3a): 154-161.

FRIERSON H F Jr, WOLBER R A, BEREAN K W, et al. Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma[J]. Am J Clin Pathol, 1995, 103(2): 195-198.

HAMMOND M E, HAYES D F, DOWSETT M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J]. Arch Pathol Lab Med, 2010, 134(6): 907-922.

DOWSETT M, NIELSEN T O, A’HERN R, et al. Assessment of Ki-67 in breast cancer: recommendations from the international Ki-67 in breast cancer working group[J]. J Natl Cancer Inst, 2011, 103(22): 1656-1664.

WOLFF A C, HAMMOND M E, HICKS D G, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update[J]. J Clin Oncol, 2013, 31(31): 3997-4013.

SYMMANS W F, PEINTINGER F, HATZIS C, et al.Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy[J]. J Clin Oncol, 2007, 25(28): 4414-4422.

OGSTON K N, MILLER I D, PAYNE S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival[J]. Breast, 2003, 12(5): 320-327.

水若鸿,杨文涛.乳腺癌Ki-67阳性指数的检测和评估[J].中华病理学杂志,2013,42(6): 420-423.

SHUI R H,YANG W T. Detection and evaluation of Ki-67 positive index in breast cancer[J]. Chin J Pathol,2013,42(6): 420-423.

LIN M X, JIN Y Z, YANG Z Y, et al. Determination and clinical significance of bone pseudoprogression in hormone receptor-positive metastatic breast cancer[J]. Ther Adv Med Oncol, 2021, 13: 17588359211022881.

ZHANG J F, LIN M X, JIN Y Z, et al. Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia[J]. Breast Cancer Res Treat, 2020, 182(3): 719-726.

《肿瘤病理诊断规范》项目组.肿瘤病理诊断规范(乳腺癌)[J].中华病理学杂志,2016,45(8): 525-528.

The Project Team of Tumor Pathological Diagnosis Standard. Diagnostic criteria for tumor pathology (breast cancer)[J]. Chin J Pathol,2016,45 (8): 525-528.

《中国乳腺导管原位癌病理诊断共识2022版》编写组.中国乳腺导管原位癌病理诊断共识(2022版)[J].中华病理学杂志,2022,51(9): 812-818.

The Writing Team of the Chinese Consensus on Pathological Diagnosis of Breast Ductal Carcinoma in situ (2022 Edition). Chinese consensus on pathological diagnosis of ductal carcinoma in situ of the breast (2022 edition)[J ] . Chin J Pathol,2022,51 (9): 812-818.

杨昭志,孟晋,马金利,等.早期乳腺癌术后靶区勾画共识[J].中国癌症杂志,2019,29(9): 753-760.

YANG Z Z,MENG J,MA J L,et al. Early stage breast cancer postoperative target volume contouring[J]. China Oncol,2019,29(9)753-760

WOLFF A C, ELIZABETH HALE HAMMOND M, ALLISON K H, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update[J]. J Clin Oncol, 2018, 36(20): 2105-2122.

WOLFF A C, SOMERFIELD M R, DOWSETT M, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update[J]. J Clin Oncol, 2023, 41(22): 3867-3872.

TARANTINO P, VIALE G, PRESS M F, et al. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer[J]. Ann Oncol, 2023, 34(8): 645-659.

SHI F, LIANG Z, ZHANG Q, et al. The performance of one-step nucleic acid amplification assay for intraoperative detection of sentinel lymph node macrometastasis in breast cancer: an updated meta-analysis[J]. Breast, 2018, 39: 39-45.

HUXLEY N, JONES-HUGHES T, COELHO H, et al. Intraoperative tests (RD-100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer[J]. Health Technol Assess, 2015, 19(2):Ⅴ-ⅩⅩⅤ.

BUNDRED J R, MICHAEL S, STUART B, et al. Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis[J]. BMJ, 2022, 378: e070346.

中国抗癌协会乳腺癌专业委员会,中华医学会肿瘤学分会乳腺肿瘤学组.中国抗癌协会乳腺癌诊治指南与规范(2024年版)[J].中国癌症杂志,2023,33(12): 1092-1187.

The Society of Breast Cancer China Anti-Cancer Association,Breast Oncology Group of the Oncology Branch of the Chinese Medical Association. Guidelines for breast cancer diagnosis and treatment by China Anti-cancer Association (2024 edition)[J]. Chin Oncol,2023,33(12): 1092-1187.

王思敏,顾雅佳.乳腺影像报告和数据系统第6版更新内容的预测[J].中华放射学杂志,2025,59(4): 358-363.

WANG S M,GU Y J. Predictions of updates to the sixth edition of the breast imaging reporting and data system[J]. Chin J Radiol,2025,59(4): 358-363.

《乳腺癌HER检测指南(2022版)》编写组.乳腺癌HER2检测指南(2024版)[J].中华病理学杂志,2024,53(12): 1192-1202.

The Writing Group of “HER Detection Guidelines for Breast Cancer”. HER2 detection guide for breast cancer (2024 edition)[J]. Chin J Pathol,2024,53(12): 1192-1202.

中国抗癌协会肿瘤标志专业委员会,上海市抗癌协会肿瘤标志物专业委员会.基于中国人群的 BRCA 胚系突变筛查专家共识(2024年版)[J ] .中国癌症杂志,2024,34(2): 220-238.

China Anti-Cancer Association Tumor Biomarker Professional Committee,Shanghai Anti-Cancer Association Tumor Biomarker Professional Committee. Expert consensus on population-based BRCA germline mutation screening in China (2024 edition)[J ] . Chin Oncol,2024,34(2): 220-238.

COLEMAN R E, COLLINSON M, GREGORY W, et al. Benefits and risks of adjuvant treatment with zoledronic acid in stage Ⅱ/Ⅲ breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)[J]. J Bone Oncol, 2018, 13: 123-135.

YANG Z Z, MENG J, MEI X, et al. Brain radiotherapy with pyrotinib and capecitabine in patients with ERBB2-positive advanced breast cancer and brain metastases: a nonrandomized phase 2 trial[J]. JAMA Oncol, 2024, 10(3): 335-341.

PERRONE F, DE LAURENTIIS M, DE PLACIDO S, et al. Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial[J]. Eur J Cancer, 2019, 118: 178-186.

李彬,陶中华,胡夕春. CDK4/6抑制剂后时代下的乳腺癌精准诊疗[J].中国癌症杂志,2025,35(3): 273-282.

LI B,TAO Z H,HU X C. Precision diagnosis and treatment of breast cancer in the post-CDK4/6 inhibitor era[J]. Chin Oncol,2025,35(3): 273-282.

HE M F, FAN W D, ZHANG X Q. Adjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysis[J]. J Hematol Oncol, 2013, 6(1): 80.

HUANG W W, HUANG C, LIU J, et al. Zoledronic acid as an adjuvant therapy in patients with breast cancer: a systematic review and meta-analysis[J]. PLo S One, 2012, 7(7): e40783.

上海市抗癌协会癌症康复与姑息治疗专业委员会,上海市抗癌协会肿瘤药物临床研究专业委员会,中国老年保健协会肿瘤防治与临床研究管理专业委员会.抗肿瘤治疗所致恶心呕吐全程管理上海专家共识(2024年版)[J].中国癌症杂志,2024,34(1): 104-134.

Cancer Rehabilitation and Palliative Professional Committee of Shanghai Anti-Cancer Association,Cancer Drug Clinical Research Committee of Shanghai Anti-Cancer Association,Cancer Prevention and Clinical Research Committee of Chinese Aging Well Association. Shanghai expert consensus on whole-process management of antineoplastic-induced nausea and vomiting (2024 edition)[J]. Chin Oncol,2024,34(1): 104-134.

中国抗癌协会肿瘤临床化疗专业委员会,中国抗癌协会肿瘤支持治疗专业委员会.肿瘤化疗导致的中性粒细胞减少诊治中国专家共识(2023版)[J].中华肿瘤杂志,2023,45(7): 575-583.

Chinese Anti-Cancer Association Committee on Clinical Chemotherapy of Tumors,Chinese Anti-Cancer Association Committee on Supportive Therapy of Tumors. China expert consensus on diagnosis and treatment of neutropenia caused by tumor chemotherapy (2023 edition)[J]. Chin J Oncol,2023,45(7): 575-583.

葛睿,王碧芸,江泽飞,等.乳腺癌CDK4/6抑制剂相关性不良反应管理共识[J].中华肿瘤杂志,2022,44(12): 1296-1304.

GE R,WANG B Y,JIANG Z F,et al. Consensus on the management of breast cancer CDK4/6 inhibitor-related adverse reactions[J]. Chin J Oncol,2022,44(12): 1296-1304.

中国医师协会肿瘤医师分会乳腺癌学组,中国抗癌协会国际医疗交流分会.中国乳腺癌抗体药物偶联物安全性管理专家共识[J].中华肿瘤杂志,2022,44(9): 913-927.

Breast Cancer Group,Branch of Oncologist,Chinese Medical Doctor Association. Chinese expert consensus of antibody-drug conjugate toxicity management for breast cancer[J]. Chin J Oncol,2022,44(9): 913-927.

王碧芸,葛睿,江泽飞,等.乳腺癌靶向人表皮生长因子受体2酪氨酸激酶抑制剂不良反应管理共识[J].中华肿瘤杂志,2020,42(10): 798-806.

WANG B Y,GE R,JIANG Z F,et al. Consensus on management of adverse reactions of breast cancer targeting human epidermal growth factor receptor 2 tyrosine kinase inhibitors[J]. Chin J Oncol,2020,42(10): 798-806.

林佳琳,王文娜,徐兵河.抗体药物偶联物在乳腺癌领域的研究现状与展望[J].中国癌症杂志,2025,35(2): 154-166.

LIN J L,WANG W N,XU B H. Current status and future perspectives of antibody-drug conjugates in breast cancer therapy[J]. Chin Oncol,2025,35(2): 154-166.

卢愚风,王晗,谢亦璠,等.中国乳腺癌重要基础转化研究——进展与展望[J].中国癌症杂志,2025,35(2): 143-153.

LU Y F, WANG H, XIE Y F, et al. Significant fundamental translational research on breast cancer in China: progress and prospects[J]. Chin Oncol, 2025, 35(2): 143-153.

抗肿瘤药物相关间质性肺病诊治专家共识专家委员会.抗肿瘤药物相关间质性肺病诊治专家共识[J].中华肿瘤杂志,2022,44(7): 693-702.

Anticancer Drug-induced Interstitial Lung Disease Management Group. Expert consensus on the diagnosis and treatment of anticancer drug-induced interstitial lung disease[J]. Chin J Oncol,2022,44(7): 693-702.

罗扬,孙涛,邵志敏,等. AK-HER2与参照药治疗HER2阳性转移性乳腺癌患者的疗效、体内代谢特征、安全性和免疫原性比较:一项多中心、随机、双盲Ⅲ期等效性临床试验[J].中国癌症杂志,2024,34(2): 161-175.

LUO Y,SUN T,SHAO Z M,et al. Efficacy,metabolic characteristics,safety and immunogenicity of AK-HER2 compared with reference trastuzumab in patients with metastatic HER2-positive breast cancer: a multicenter,randomized,double-blind phase Ⅲ equivalence trial[J]. Chin Oncol,2024,34(2): 161-175.

FAN L, WANG Z H, MA L X, et al. Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial. Lancet Oncol, 2024, 25(2):184-197.

SCHMID P, CORTES J, PUSZTAI L, et al. Pembrolizumab for early triple-negative breast cancer[J]. N Engl J Med, 2020, 382(9): 810-821.

SCHMID P, CORTES J, DENT R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer[J]. N Engl J Med, 2022, 386(6): 556-567.

SCHMID P, CORTES J, DENT R, et al. Overall survival with pembrolizumab in early-stage triple-negative breast cancer[J]. N Engl J Med, 2024, 391(21): 1981-1991.

SHEPHERD J H, BALLMAN K, POLLEY M C, et al. CALGB 40603 (alliance): Long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer[J]. J Clin Oncol, 2022, 40(12): 1323-1334.

SLAMON D, LIPATOV O, NOWECKI Z, et al. Ribociclib plus endocrine therapy in early breast cancer[J]. N Engl J Med, 2024, 390(12): 1080-1091.

ZHU X D, ZHU T, GU X. WITHDRAWN: Letter Re: a phaseⅢ trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial[J]. Ann Oncol, 2025: S0923753425008166.

JOHNSTON S R D, HARBECK N, HEGG R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR + , HER2 - , node-positive, high-risk, early breast cancer (monarch E)[J ] . J Clin Oncol, 2020, 38(34): 3987-3998.

JOHNSTON S R D, TOI M, O’SHAUGHNESSY J, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarch E): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2023, 24(1): 77-90.

RASTOGI P, O’SHAUGHNESSY J, MARTIN M, et al. Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarch E overall survival interim analysis, including 5-year efficacy outcomes[J]. J Clin Oncol, 2024, 42(9): 987-993.

TUTT ANJ, GARBER JE, KAUFMAN B, et al. Adjuvant olaparib for patients with BRCA1 - or BRCA2 -mutated breast cancer[J ] . N Engl J Med, 2021, 384(25): 2394-2405.

GEYER CE JR, GARBER JE, GELBER RD, et al. Overall survival in the Olympi A phase Ⅲ trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer[J ] . Ann Oncol, 2022, 33(12): 1250-1268.

HUANG L, PANG D, YANG H J, et al. Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase Ⅲ PEONY trial[J]. Nat Commun, 2024, 15(1): 2153.